Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET

Company Participants

Tom Galassi - Investor Relations, LifeSci Advisors

Chaim Lebovits - Chief Executive Officer

Stacy Lindborg - Executive Vice President and Chief Development Officer

Ralph Kern - President and Chief Medical Officer

Alla Patlis - Interim Chief Financial Officer

David Setboun - Executive Vice President and Chief Operating Officer

Conference Call Participants

David Bautz - Zacks Small-Cap

Daniel Walker - Ness Industries

Operator

Greetings ladies and gentlemen and welcome to the Brainstorm Cell Therapeutics Second Quarter 2022 Conference Call. At this time, participants are in a listen-only mode. As a reminder, this call is being recorded.

And I would now like to introduce your host for today's conference, Mr. Tom Galassi of LifeSci Advisors. Mr. Galassi, you may begin.

Tom Galassi

Good morning and thank you for joining us. Before we begin the opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative orders, such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2022 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support their business planning efforts.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time-to-time in its SEC filings. The company's results may differ materially from those projected on today's call. The company undertakes no obligation to publicly update any forward-looking statements.

Joining me on the call today will be Chaim Lebovits, Chief Executive Officer of Brainstorm; Dr. Stacy Lindborg, Executive Vice President and Chief Development Officer; Dr. Ralph Kern, President and Chief Medical Officer; and Alla Patlis, Interim Chief Financial Officer. In addition, Dr. David Setboun, Executive Vice President and Chief Operating Officer is also on the call and will be available to answer your questions during the Q&A session.

Now, I would like to turn the call over to Mr. Lebovits. Please go ahead.

Chaim Lebovits

Thanks, Tom and thank you to all listening for joining us to discuss our second quarter financial results and corporate highlights. I expect most of you have read our press release by now and you will be able to see that we have been working very hard behind the scenes. We’ve been extremely disciplined by remaining quiet until today about our intentions to submit a BLA for NurOwn. We are very excited to have this Q2 earnings call and to provide you with an update.